Trial Profile

A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ianalumab (Primary) ; Corticosteroids; Corticosteroids
Indications Idiopathic thrombocytopenic purpura
Focus Registrational; Therapeutic Use
Acronyms VAYHIT1
Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

20 Aug 2024 Planned End Date changed from 4 Feb 2028 to 18 Dec 2028.
20 Aug 2024 Planned primary completion date changed from 25 Sep 2025 to 24 Apr 2026.
05 Oct 2023 Planned End Date changed from 25 Feb 2028 to 4 Feb 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com